射频消融在肝癌多学科综合治疗中的应用

陈敏山; 刘芙蓉

射频消融在肝癌多学科综合治疗中的应用

中山大学肿瘤防治中心肝胆外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3729
- HTML全文浏览量: 26
- PDF下载量: 888
- 被引次数: 0
出版历程
- 收稿日期: 2010-12-30
- 出版日期: 2011-04-20

The role of radiofrequency ablation in multidisciplinary treatment of hepatocellular carcinoma

摘要

摘要: 以射频消融(RFA)为代表的局部消融治疗已成为肝癌的重要治疗手段,在肝癌治疗中得到广泛的应用。其主要适应证为肿瘤单发、直径≤5 cm;或者肿瘤2～3个、最大直径≤3 cm。数个临床研究表明射频治疗小肝癌的效果与手术切除相当,国内外多个肝癌临床治疗指南已经将射频与手术切除一样,并列为小肝癌的根治性治疗方法。临床上RFA常常与手术切除、血管介入、瘤内无水酒精注射术、放射治疗、化疗、靶向药物治疗、免疫生物治疗等方法联合应用,在肝癌多学科综合治疗领域中起着越来越重要的作用。
- 导管消融术 /
- 肝肿瘤
Abstract: Radiofrequency ablation (RFA) has been an important treatment for hepatocellular carcinoma (HCC) .The good candidates of RFA are patients with HCC at early stage (solitary≤5 cm in diameter or ≤3 nodules, ≤3 cm in diameter) .Several clinical trials have shown that RFA was as effective as resection in the treatment of small HCC.Until now, RFA has been widely used as a radical treatment for small HCC.RFA also plays an important role in multidisciplinary treatment of HCC and usually combines with other therapies such as resection, vascular intervention, intra-tumor ethanol injection, radiotherapy, chemotherapy, targeted drug therapy, biological immune therapy.
- catheter ablation /
- liver neoplasms

HTML全文

参考文献(26)

[1]WHO IARC Report.GLOBOCAN[R].FAST STATS, 2008.http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900.

[2]Guglielmi A, Ruzzenente A, Valdegamberi A, et al.Radiofrequency ablation versus surgical resection for thetreatment of hepatocellular carcinoma in cirrhosis[J].JGastrointest Surg, 2008, 12 (1) :192-198.

[3]Lu MD, Kuang M, Liang LJ, et al.Surgical resection versuspercutaneous thermal ablation for early-stage hepatocellularcarcinoma:a randomized clinical trial[J].Zhonghua Yi XueZa Zhi, 2006, 86 (12) :801-805.

[4]Montorsi M, Santambrogio R, Bianchi P, et al.Survival andrecurrences after hepatic resection or radiofrequency forhepatocellular carcinoma in cirrhotic patients:a multivariateanalysis[J].J Gastrointest Surg, 2005, 9 (1) :62-67.

[5] Hong SN, Lee SY, Choi MS, et al.Comparing the outcomes ofradiofrequency ablation and surgery in patients with a singlesmall hepatocellular carcinoma and well-preserved hepaticfunction[J].J Clin Gastroenterol, 2005, 39 (3) :247-252.

[6]Lupo L, Panzera P, Giannelli G, et al.Single hepatocellularcarcinoma ranging from 3 to 5 cm:radiofrequency ablationor resection?[J].HPB (Oxford) , 2007, 9 (6) :429-434.

[7]Chen MS, Li JQ, Zheng Y, et al.A prospective randomizedtrial comparing percutaneous local ablative therapy andpartial hepatectomy for small hepatocellular carcinoma[J].Ann Surg, 2006, 243 (3) :321-328.

[8]Livraghi T, Meloni F, Di Stasi M, et al.Sustained completeresponse and complications rates after radiofrequencyablation of very early hepatocellular carcinoma in cirrhosis:Is resection still the treatment of choice?[J].Hepatology, 2008, 47 (1) :82-89.

[9]Lau WY, Lai EC.The current role of radiofrequencyablation in the management of hepatocellular carcinoma:asystematic review[J].Ann Surg, 2009, 249 (1) :20-25.

[10]Fisher RA, Maluf D, Cotterell AH, et al.Non-resective ablationtherapy for hepatocellular carcinoma:effectiveness measuredby intention-to-treat and dropout from liver transplant waitinglist[J].Clin Transplant, 2004, 18 (5) :502-512.

[11]Mazzaferro V, Battiston C, Perrone S, et al.Radiofrequencyablation of small hepatocellular carcinoma in cirrhoticpatients awaiting liver transplantation:a prospectivestudy[J].Ann Surg, 2004, 240 (9) :900-909.

[12]Pawlik TM, Izzo F, Cohen DS, et al.Combined resection andradiofrequency ablation for advanced hepatic malignancies:results in 172 patient[J].Ann Surg Oncol, 2003, 10 (9) :1059-1069.

[13]Choi D, Lim HK, Joh JW, et al.Combined hepatectomyand radiofrequency ablation for multifocal hepatocellularcarcinomas:long-term follow-up results and prognosticfactors[J].Ann Surg Oncol, 2007, 14 (12) :3510-3518.

[14]Taniai N, Yoshida H, Mamada Y, et al.Is intraoperative adjuvanttherapy effective for satellite lesions in patients undergoingreduction surgery for advanced hepatocellular carcinoma?[J].Hepatogastroenterology, 2006, 53 (68) :258-261.

[15]Minagawa M, Makuuchi M, Takayama T, et al.Selection criteriafor repeat hepatectomy in patients with recurrent hepatocellularcarcinoma[J].Ann Surg, 2003, 238 (5) :703-710.

[16]Poon RT, Fan ST, Lo CM, et al.Intrahepatic recurrence aftercurative resection of hepatocellular carcinoma:long-termresults of treatment and prognostic factors[J].Ann Surg, 1999, 229 (2) :216-222.

[17]Kakazu T, Makuuchi M, Kawasaki S, et al.Repeat hepaticresection for recurrent hepatocellular carcinoma[J].Hepatogastroenterology, 1993, 40 (4) :337-341.

[18]Choi D, Lim HK, Kim MJ et al.Recurrent hepatocellularcarcinoma:percutaneous radiofrequency ablation afterhepatectomy[J], Radiology, 2004, 230 (1) :135-141.

[19]Liang HH, Chen MS, Peng ZW, et al.Percutaneousradiofrequency ablation versus repeat hepatectomy forrecurrent hepatocellular carcinoma:a retrospective study[J].Ann Surg Oncol, 2008, 15 (12) :3484-3493.

[20]Veltri A, Moretto P, Doriguzzi A, et al.Radiofrequencythermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-earlyhepatocellular carcinoma (hepatocellular carcinoma) [J].EurRadiol, 2006, 16 (3) :661-669.

[21]Monsky WL, Kruskal JB, Lukyanov AN, et al.Radiofrequencyablation increases intratumoral liposomal doxorubicinaccumulation in an animal breast tumor model[J].Radiology, 2002, 224 (3) :823-829.

[22]Hou YB, Chen MH, Yan K, et al.Adjuvant percutaneousradiofrequency ablation of feeding artery of hepatocellularcarcinoma before treatment[J].World J Gastroenterol, 2009, 15 (21) :2638-2643.

[23]Zhang YJ, Liang HH, Chen MS, et al.Hepatocellularcarcinoma treated with radiofrequency ablation with orwithout ethanol injection:a prospective randomized trial[J].Radiology, 2007, 244 (2) :599-607.

[24]Llovet JM, S Ricci, Mazzaferro V, et al., Sorafenib inadvanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.

[25]Forner A, Reig ME, de Lope CR, et al.Current strategyfor staging and treatment:the BCLC update and futureprospects[J].Semin Liver Dis, 2010, 30 (1) :61-74.

[26]Ma HQ, Zhang YJ, Wang QJ, et al.Therapeutic safety andeffects of adjuvant autologous RetroNectin activated killercell immunotherapy for patients with primary hepatocellularcarcinoma after radiofrequency ablation[J].Cancer BiolTher, 2010, 9 (11) :903-907.

施引文献

资源附件(0)

访问统计